Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:NVET

(NVET) (NVET) Stock Price, News & Analysis

(NVET) logo

About (NVET) Stock (NASDAQ:NVET)

Key Stats

Today's Range
$6.72
$6.72
50-Day Range
N/A
52-Week Range
$2.75
$6.76
Volume
N/A
Average Volume
38,104 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Nexvet Biopharma public limited company is a clinical-stage biopharmaceutical company focused on transforming the therapeutic market for companion animals by developing and commercializing species-specific biologics. The Company’s platform technology, which it refers to as PETization, is an algorithmic approach that enables the Company to create monoclonal antibodies (mAbs) a type of biologic, that are designed to be recognized as self or native by an animal’s immune system, a property referred to as 100% species-specificity. PETization is designed to build upon the safety and efficacy data from clinically tested human therapies to create new therapies for companion animals. Biologics generally include mAbs, which are targeted antibodies derived from identical (clonal) cells. The Company’s advanced product candidates are in pivotal-phase development: ranevetmab (or NV-01) and frunevetmab (or NV-02).

Receive NVET Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for (NVET) and its competitors with MarketBeat's FREE daily newsletter.

NVET Stock News Headlines

Bill Gates’ is about to mint millionaires (again) with Stargate.
This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrough so advanced, it’s going to make ChatGPT look like VHS. But what’s even more unbelievable? I believe it’ll make Nvidia’s meteoric rise look like a backyard bottle rocket.
Nymox Pharmaceutical Corporation News
See More Headlines

NVET Stock Analysis - Frequently Asked Questions

(NVET) (NASDAQ:NVET) issued its quarterly earnings results on Thursday, May, 11th. The biopharmaceutical company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.49) by $0.02.

(NVET) (NVET) raised $58 million in an initial public offering on Thursday, February 5th 2015. The company issued 4,000,000 shares at $13.00-$16.00 per share. BofA Merrill Lynch and Cowen and Company acted as the underwriters for the IPO and Piper Jaffray and JMP Securities were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that (NVET) investors own include Frontline (FRO), Achillion Pharmaceuticals (ACHN), Anthera Pharmaceuticals (ANTH), Sphere 3D (ANY), Arena Pharmaceuticals (ARNA), Yamana Gold (AUY) and BioLineRx (BLRX).

Company Calendar

Last Earnings
5/11/2017
Today
11/24/2024

Industry, Sector and Symbol

Sector
N/A
Industry
N/A
Sub-Industry
N/A
Current Symbol
NASDAQ:NVET
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

This page (NASDAQ:NVET) was last updated on 11/24/2024 by MarketBeat.com Staff
From Our Partners